

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3315208/lu-li-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

3,506
citations

13
h-index

25
g-index

25
ext. papers

4,702
ext. citations

11
avg, IF

5.05
L-index

#	Paper	IF	Citations
22	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018 , 359, 926-930	33.3	1204
21	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , 2016 , 8, 346ra92	17.5	688
20	Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. <i>Science</i> , 2017 , 355, 1330-1334	33.3	543
19	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 10202-10207	11.5	303
18	Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. <i>JAMA Oncology</i> , 2019 , 5, 1710-1717	13.4	177
17	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019 , 68, 663-671	19.2	138
16	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	110
15	Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019 , 5, 1118-1123	13.4	85
14	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. <i>ELife</i> , 2018 , 7,	8.9	72
13	A multimodality test to guide the management of patients with a pancreatic cyst. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	71
12	Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021 , 148, 1014-1026	7.5	26
11	Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 476, 423-429 ^{5.1}	5.1	18
10	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021 , 18, e1003620	11.6	16
9	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3516-3516	2.2	13
8	The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3521-3521	2.2	9
7	The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. <i>International Journal of Cancer</i> , 2019 , 145, 540-547	7.5	8
6	Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4101-4101	2.2	6

5	Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16206-e16206	2.2	4
4	The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3511-3511	2.2	3
3	Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer. <i>ELife</i> , 2021 , 10,	8.9	2
2	A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3518-3518	2.2	1
1	Larger organ size caused by obesity is a mechanism for higher cancer risk		1